Company news
Passage Bio, Inc. news in 2020
Passage Bio, Inc.'s news releases, calls and decks from 2020, newest first.
Passage Bio Announces Gene Therapy Manufacturing Research and Development Site
December 15, 2020
Passage Bio Receives MHRA Clinical Trial Authorization for PBGM01 for Treatment of GM1 Gangliosidosis
December 9, 2020
Passage Bio Teams with Catalent to Start CGMP Manufacturing for Lead Gene Therapy Products
December 6, 2020
Passage Bio Reports Third Quarter 2020 Financial Results and Recent Business Highlights
November 9, 2020
Passage Bio and Invitae Announce Collaboration to Facilitate Genetic Testing to Support Early Diagnosis and Greater Awareness of Clinical Trials for Patients with GM1
November 8, 2020
Passage Bio to Report Third Quarter 2020 Financial Results on November 10, 2020
November 3, 2020
Passage Bio’s PBKR03 Receives Orphan Drug and Rare Pediatric Disease Designations from FDA for Treatment of Krabbe Disease
October 27, 2020
Passage Bio’s PBGM01 Receives Orphan Drug Designation from EMA for Treatment of GM1 Gangliosidosis
October 25, 2020
Passage Bio Announces Publication of Preclinical Data That Show Single Injection of Optimized AAV Vector into Cerebral Spinal Fluid Corrects Neurological Disease, Supporting Advancement of PBGM01 into Clinic
October 12, 2020
Passage Bio Announces Publication of Preclinical Gene Therapy Study Data from Frontotemporal Dementia Program
September 16, 2020
Passage Bio Reports Second Quarter 2020 Financial Results and Recent Business Highlights
August 12, 2020
Passage Bio to Report Second Quarter 2020 Financial Results on August 13, 2020
August 6, 2020
Passage Bio Receives Rare Pediatric Disease Designation for PBGM01 for Patients with GM1 Gangliosidosis
May 20, 2020
Passage Bio Announces Presentation of Data from Animal Models of Krabbe Disease at the American Society of Gene & Cell Therapy (ASGCT) 23rd Annual Meeting
May 11, 2020
Passage Bio Reports First Quarter 2020 Financial Results and Recent Business Highlights
May 10, 2020
Passage Bio Announces Expansion of Gene Therapy Collaboration with University of Pennsylvania
May 6, 2020
Passage Bio to Report First Quarter 2020 Financial Results on May 11, 2020
May 3, 2020
FDA Grants Passage Bio Orphan Drug Designation for PBGM01 for Treatment of Infantile GM1 Gangliosidosis
April 20, 2020
Passage Bio Announces Exercise of Underwriters’ Option to Purchase Additional Shares
March 8, 2020
Passage Bio Appoints Athena Countouriotis to Board of Directors
March 4, 2020
Passage Bio Announces Pricing of Initial Public Offering
February 26, 2020
Calls in 2020
Decks in 2020
- Investor Presentation (September 2020)
Investor deck · 39 slides · Sep 9, 2020